everyone. and Roger, call. welcome, you, for Thanks the joining Thank
XXX,XXX quarter. with more at to segment total record prescriptions during continues third than prescription the core high-level fiscal perform Our of a
pediatric the compared ago ADHD were year our scripts up were XX% XX%, to Our scripts up period. while
of disruptions, notably of total presented job testament done generic Aytu market the growth supply continued recently, ongoing the an we've by the the the XX% and capabilities exceptional RxConnect most our unique combined to XR, the prescriptions strong disruptions. Further a shortages that, methylphenidate more platform. along ADHD team, with to commercial execution in maximizing The Adderall is opportunity the
press of saw a portfolio, likely within between you reported bit our there's release, the in little revenue as net disconnect quarter. But this and the prescription growth ADHD especially a
dive me a market and responsive products increase up effective for with dynamics we keep to To details. costs, to some be rising in price April Let for implemented ADHD X.
a of As million revenue reduction we during a resulted third result, a recorded quarter. adjustment channel of onetime $X.X in the which
year-over-year. offers savings against patient to our of and company. this deductibles in continues to of to this gross market payer ADHD continues Excluding Rx would each our backdrop The beginning segment to robust resetting these time of adjustment, for the have X% reception Absent a that products at year difference the the that nets calendar net insurance patient underlying provide tailwinds changes relates revenue impact to increased year. the remaining the items, be
in the On up the on year prescriptions high-level million with the line extensions detail quarter. $X.X at new and we at during XX% to revenue pediatric net XX% segment third the momentarily, our planned side, portfolio peds to more for quarter a and continues ago fiscal the expand perform Rx I'll multivitamins. compared year's have to including
several products sales our channel channel. This period. implemented the side, direct e-commerce we resulted the focus initiative on launch launch begun XX% the the had On transition through continue with phase medicines out consumer as planning Health We're channel. year are we Amazon OTC and of of we this the various C'rcle strategic on mail later and shift the a with ago in now health the increasing to in compared a soft branding year,
return more to higher lead customer repeat build will believe We improve ad purchases. and branding on our equity, spend
profitable. segment focus future squarely this in consumer see I'll expand on a within moment. more will we as segment getting bit improvement a We health on this the
payer during Rx quarter, for So achieve the pricing dynamics I mentioned, channel said we EBITDA coupled with items and on effects strong we adjusted achieve the we positive the to the positive segment. that the third That allow the positive didn't end year-to-date and adjusted but QX in the improvement note. the of timing should we overall in of and believe companywide due absence EBITDA pricing, us EBITDA to are these business momentum a have year still
up shaping momentum days perspective to through of much quarter, excuse is are up And factory we the of have factory first year shipments And shipments to peds number XX up shipping same through the and get quarter. XX% days shipping XX, which ADHD do last is current last how quarter, on over me. yesterday XX% over the say last quarter product -- May how the are
shipments how XX% When just growth year, the XX% shipments are is May impressive currently Rxs are and at XXX% last to X those an performing. April estimated last looking numbers year larger. April. this versus well ped same Adzenys from up X over ADHD illustrate shipments up up dates are April Adzenys and are even
the we're with say pleased least, to quite So momentum. our continuing
microparticle first disintegrating into more Rx the beginning release with and bit as business a the segment orally platform. commercial treatment our respectively stimulant tablets and utilize our a drug for release which only These amphetamine of extended XR-ODT methylphenidate Cotempla medications novel FDA portfolio, and are delivery ADHD. modified proprietary and that dive technology formulated extended-release Let's XR-ODT, Adzenys ODTs, includes approved ADHD a the
few about trends intact, remain extremely quarter delays third in strong the few the the supply various XX% and in we've ADHD increase As with Adderall an up and generic last I quarter this XR we we we've see market as during to The the ADHD an continue including scripts discussed manufacture mentioned, prescription diagnoses impacts quarters. overall had talked quarters growth over disruptions year-over-year. the from growth long-term last
to of & Johnson's shortages hear Concerta-authorized of confirmed continuing we're the Also, methylphenidate Johnson and discontinuation generic.
present market significant persist brands a factors growth have brands. ADHD we compelling providing these our opportunity for and of tailwinds some both believe may time that now So for
population to have ADHD ages XX data been an CDC somewhere and has million CDC X XXXXs XXXX. both X XX% grown on XX% through that continue medication The -- XX% with survey in see treatment estimates We ADHD to approximately patient between and/or figures X.X million The from million of This the X figure. actually diagnosed that these various treatment. cites since through behavioral increase approximately by therapy. receive states awareness reports XXXX children of based kids
especially ADHD received XX,XXX Thus, X almost and of the post-COVID study kids especially population mental parent health that treatment about recent reported found parent ever a that need in suggests treatment. period, of girls XX% with ages with a potentially study and pervasive this XX had the only kids reported exist outpatient children, care. larger gaps ADHD in of in of is Interestingly,
been While among about adult debate also adults prescriptions concerning uptick study ADHD CDC has the questions March sufferers. a size adult to recognized the COVID the years. actual of the treat the showed concurrent the suggests also from stimulant A XXXX in ADHD are over ADHD childhood there increasingly large pandemic. population, report with
these population persisted. XX% from supply increase numerous reporting XXXX timeframe. employer first even year, largest XXXX showed X a the the In single increase in media sponsored market articles the continued disruptions the Insurance news disruptions with Yet expands, this plans on XXXX, with months diagnosed XXXX as year from this. attention to current on of the claims
uninterrupted. has supply our Fortunately, remained
past disruptions the to we over few as gain believe expect and prescribers supply enabled have and this way patients market persist I quarters find mindshare, Adzenys. to the Adzenys to and new their
of so Adderall Adzenys brand a the XR, remnants as our approved is shortage additional to to well-positioned amphetamine reminder, bioequivalence As remain. extended capture the release continue to share as is
We're the believe will supply and have ever disruptions on long a after our strong levels average than weekly have dissipated. trajectory higher And before. persist reset we that TRx
few the of As in continued we a pursuit lengthy profitability, key and undertaken one of Cotempla. goal important late. is of has manufacturing Adzenys the we hit quarters markers the number of a have outsourced of discussed This been process, but for a initiatives have we've on of now,
Adzenys was This third-party approval one transfer enables approval One milestones of two prior key -- achieved PAS. supplement, of the the of we FDA designated our approval to miles of the of Adzenys the manufacturer. manufacturing key the
to completed, mid expect 'XX. site FDA bioequivalence the in calendar approval second been to The Cotempla FDA milestone, transfer by we has enable PAS could successfully the study This Cotempla the submit late and 'XX. calendar
transfers an As completion site of we Prairie of and have of products exiting XX% brands. ADHD estimated Texas the realize the Grand both improvement to the upon communicated, the we expect margin facility,
the made the of in progress sublease to we in throughout key of is facility. with expense portion on Prairie This of we a both of step forward our reduction, step another look in year. and I'm ADHD interim the definitely front calendar manufacturing short-term fully exit margins continued significant the products improving and our as pleased the site. Grand Another the goal the was overhead term this progress this through forward took longer
Let's to containing pediatric and infants our prescription with Tri-Vi-Flor. and deficiency. product Poly-Vi-Flor of portfolio, which and lines Two formulations combinations for includes multivitamin in complementary vitamins children fluoride-based various transition fluoride fluoride
markets released an products and competitive patient established also for over older. branded patients and years treat generic We indicated products. features extended carbinoxamine These X based pediatric market and distinct benefits ER, suspension to numerous serve both Karbinal conditions antihistamine offer clinical and allergic
quarter. to revenues providing as awareness we remarkable $X.X significantly drivers key TVF The to trajectory. a These and in Since products platform prescription million revenues increasing here PVF in grown the platform, Aytu we are $X.X the commercial with have ago tailwinds quarter, line, prescription leverage. added ramping the we XX% RxConnect ongoing achieved improvements and from During growth the growth. execution to RxConnect pediatric year growth as well for continue demonstrate product compared the and million are prescription to
only or like that is to water. The in most the Jersey, XX% data less. some And New U.S CDC mid-teens the access in fluoridated states recent has of that shows population percentage
additional the evaluating line as supplementation. growth look areas fluoride need continually are in We of we opportunities to fluoride for multivitamin
enhanced of also molecular In improved excellent body ingredient of the a addition water weight a yield low launching higher levels overall other available the we're Arcofolin's purity offers stability tailwinds, line an on with ion and market. profile. Arcofolin a profile, and folate forms also extension assay than folate solubility water of elemental currently counter and an Metafolin Tri-Vi-Flor has of improved an folic It acid L-methylfolate. content the low to as Arcofolin. profile ready novel Poly-Vi-Flor
lines extend growth differentiation unique transition going to products multivitamin novel and continued forward. provides patent product the portfolio and Arcofolin look further life to the Tri-Vi-Flor our of forward profile, to with adoption Poly-Vi-Flor addition brands these the of we ingredient. We this believe also pediatric improve Arcofolin and will and The
across the revenue experienced portfolio. we our pleased and traction I'm positive execution of segment can levels strategies, record trends at expected I segment. successful our the outlay is company with pediatric bright long-term XX% are with very we're the achieving in our scripts various Rx Overall, for net ADHD growth to the profitability. the margin to coupled With consistent continue enhancement believe and carry
Consumer our to now Health segment. transition Let's
As Health, Amazon management platform. diabetes categories and a all core reminder, within directly focuses regrowth, sell hair platforms, brands. e-commerce based Consumer branded on products health, value national to including such competing We through with as branded in digestive websites large allergy, the competing product consumers our and
Consumer has sold through the products Additionally, segment direct historically mail.
on we As margin been on quarters, segment, focus sales higher of efficient has improve last profitability our touched Health the contribution to few historically with the more channels. online the a Consumer objective
counter specifically and to we channel may impact and or the in a near-term, our our mail the company, entire revenue direct order segment will EBITDA EBITDA profit in phasing result, This are Consumer focus out Very is over long medicines, positive OTC focus within the and drive segment profitability. e-commerce the channel. shift across companywide clearly negatively Health through on on higher improved in As run. but driving the growth the
revenue quarter, to the ago the year down period. was During compared XX%
our did year, Amazon back of and gave benefit bit were competing anomaly, We encounter during incremental which a driven sales pickup from However, big Regoxidine our and marketing a a costs ad Also, of primarily sales through product spend. Rogaine was the e-commerce XX%. us XXXX. for quarter in by last we an increased shortage up
year. future establishment A value the growth Health, is part called family Health's a which plan we this brand to Consumer C'rcle expect officially later of big of launch
have may we've that products under begun the already our on storefront. You out rolling Amazon seen brand
but spend, on being to repeat to incremental more our help value our a brand medicines drive through a collective a brand believe of range profitability. improved build have single work Health OTC is represent showcasing of made. recognize progress product return the Health recognized equity based and We We C'rcle addressing segment, customers overall conditions. OTC medicine family and brand ad Consumer will to still benefits segment within fully do family
let the Mark? CFO, to some overview, it color turn to that our me additional Oki, Mark over add with to So numbers.
